SYNOPSIS The efficacy of naproxen, a potent prostaglandin synthetase inhibitor, in migraine prophylaxis was assessed in a double‐blind placebo‐controlled cross‐over study in 28 migraine patients. After a drug‐free interval of at least 2 months, placebo and naproxen were given for 6 weeks each, with an interposed placebo week in between the two treatment periods. The dose of naproxen was 250 mg b.i.d. Naproxen seems to exert a moderate, but significant beneficial effect, with regard to headache days as well as headache indices. In a direct comparison, a significant number of patients preferred naproxen to placebo. Side effects were negligible. A systematic search for substances with antimigrainous properties should be made among the nonsteroidal, anti‐inflammatory group substances.
No takes yet. Share an insight, caveat, or question.
Lindegaard et al. (1980) studied this question.